|
FDA Approves Medivation, Astellas’ Xtandi for Prostate Cancer
Medivation and Astellas expect their oral prostate cancer treatment Xtandi will be available mid-September, following an Aug. 31 FDA approval.
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives